Literature DB >> 21282717

Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.

Martin Jädersten, Aly Karsan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21282717      PMCID： PMC3031681          DOI： 10.3324/haematol.2010.038281

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

1.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.

Authors:  Jacqueline Boultwood; Carrie Fidler; Amanda J Strickson; Fiona Watkins; Susana Gama; Lyndal Kearney; Sabrina Tosi; Arek Kasprzyk; Jan-Fang Cheng; Rina J Jaju; James S Wainscoat
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

Review 2.  The evolution of thalidomide and its IMiD derivatives as anticancer agents.

Authors:  J Blake Bartlett; Keith Dredge; Angus G Dalgleish
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

Review 5.  Genetics of therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  J Pedersen-Bjergaard; M K Andersen; M T Andersen; D H Christiansen
Journal:  Leukemia       Date:  2008-01-17       Impact factor: 11.528

Review 6.  Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.

Authors:  B L Ebert
Journal:  Leukemia       Date:  2009-03-26       Impact factor: 11.528

7.  A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.

Authors:  Sheng Wei; Xianghong Chen; Kathy Rocha; P K Epling-Burnette; Julie Y Djeu; Qing Liu; John Byrd; Lubomir Sokol; Nick Lawrence; Roberta Pireddu; Gordon Dewald; Ann Williams; Jaroslaw Maciejewski; Alan List
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-26       Impact factor: 11.205

8.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.

Authors:  A A N Giagounidis; U Germing; S Haase; B Hildebrandt; B Schlegelberger; C Schoch; L Wilkens; M Heinsch; H Willems; M Aivado; C Aul
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

9.  Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.

Authors:  Andrea Pellagatti; Eva Hellström-Lindberg; Aristoteles Giagounidis; Janet Perry; Luca Malcovati; Matteo G Della Porta; Martin Jädersten; Sally Killick; Carrie Fidler; Mario Cazzola; James S Wainscoat; Jacqueline Boultwood
Journal:  Br J Haematol       Date:  2008-05-08       Impact factor: 6.998

10.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.

Authors:  Benjamin L Ebert; Jennifer Pretz; Jocelyn Bosco; Cindy Y Chang; Pablo Tamayo; Naomi Galili; Azra Raza; David E Root; Eyal Attar; Steven R Ellis; Todd R Golub
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962
View more
  3 in total

Review 1.  5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).

Authors:  Hiroshi Ureshino; Haruna Kizuka; Kana Kusaba; Haruhiko Sano; Atsujiro Nishioka; Takero Shindo; Yasushi Kubota; Toshihiko Ando; Kensuke Kojima; Shinya Kimura
Journal:  Int J Hematol       Date:  2016-12-02       Impact factor: 2.490

2.  Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C.

Authors:  Lindsey Skrdlant; Jeremy M Stark; Ren-Jang Lin
Journal:  BMC Mol Biol       Date:  2016-08-23       Impact factor: 2.946

3.  Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report.

Authors:  Hai-Ping Liang; Xing-Chun Luo; Ya-Li Zhang; Bei Liu
Journal:  World J Clin Cases       Date:  2022-04-16       Impact factor: 1.337
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.